Buy Stocks Easy | About Us

June 28, 2022

OBSV

Buy ObsEva SA Stock (symbol: OBSV) Easy Online

Company Name: ObsEva SA

Symbol: OBSV

Sector: Health Care

Industry: Major Pharmaceuticals

IPO: 2017

OBSV Current Share Price

Today's OBSV ( ObsEva SA ) opening price: $

Yesterday's OBSV ( ObsEva SA ) closing price: $

ObsEva SA Stock ( symbol: OBSV ) Price Chart since IPO (2017):

12 Months ObsEva SA Stock ( symbol: OBSV ) Price Chart

Popular Questions about ObsEva SA Public Stock ( OBSV )

A: ObsEva SA stock symbol (also called stock or share ticker) is OBSV

A: ObsEva SA IPO (Initial Public Offering) took place on 2017

A: ObsEva SA's stock (OBSV symbol) price at ther IPO (initial Public Offering) was $

Q: Is OBSV stock worth buying at the moment?

A: The OBSV stock performance since 2019 are rather disappointing. If you had bought 1 share of ObsEva SA stock (symbol: OBSV) at the beginning of 2019, at the opening share price of $12.6700, you would be left with exactly $ - which means a waste of your money and time. - SHOW ONLY IF equal or loose.

Buy ObsEva SA Stock Easy Online

ObsEva SA Stock Ticker Price Chart since IPO:

ObsEva SA Stock Price Yesterday

ObsEva SA Stock Price – Last Week

ObsEva SA Stock Price – Last Month

ObsEva SA Stock Value Chart – 12 Months

Rate this post

Latest Stock News:

http://www.zacks.com/stock/news/652183/obseva-sees-hammer-chart-pattern-time-to-buy

ObsEva Sees Hammer Chart Pattern: Time to Buy?

ObsEva has been struggling lately, but the selling pressure may be ...

http://www.zacks.com/stock/news/621549/obseva-enters-oversold-territory

ObsEva Enters Oversold Territory

ObsEva SA has been on a bit of a cold streak lately, but there migh...

http://www.zacks.com/stock/news/608004/obseva-sa-obsv-reports-q3-loss-misses-revenue-estimates

ObsEva SA (OBSV) Reports Q3 Loss, Misses Revenue Estimates

ObsEva SA (OBSV) delivered earnings and revenue surprises of 23.17%...

http://www.globenewswire.com/news-release/2019/11/07/1942789/0/en/Obseva-Announces-That-Nolasiban-Implant-4-Study-Did-Not-Meet-Primary-Endpoint.html

Obseva Announces That Nolasiban Implant 4 Study Did Not Meet Primary Endpoint

ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company ...

http://www.globenewswire.com/news-release/2019/10/31/1938446/0/en/ObsEva-Announces-Clearance-to-Initiate-Pivotal-US-Phase-3-Clinical-Trial-IMPLANT-3-of-Nolasiban-in-Women-Undergoing-Embryo-Transfer-Following-IVF.html

ObsEva Announces Clearance to Initiate Pivotal US Phase 3 Clinical Trial (IMPLANT 3) of Nolasiban in Women Undergoing Embryo Transfer Following IVF

Geneva, Switzerland and Boston, MA – October 31, 2019 – ObsEva SA ...

http://www.globenewswire.com/news-release/2019/10/11/1928405/0/en/ObsEva-SA-to-Present-Model-Based-Analysis-Supporting-Clinical-Use-of-Linzagolix-at-Doses-Not-Requiring-Hormonal-Add-back-Therapy.html

ObsEva SA to Present Model-Based Analysis Supporting Clinical Use of Linzagolix at Doses Not Requiring Hormonal Add back Therapy

Once-daily oral Linzagolix doses of 75 mg and 100 mg without hormon...

http://www.globenewswire.com/news-release/2019/10/09/1927040/0/en/ObsEva-SA-to-Present-New-Clinical-Data-on-its-Lead-Compounds-Nolasiban-and-Linzagolix-at-the-75th-Annual-ASRM-Meeting-in-Philadelphia-PA.html

ObsEva SA to Present New Clinical Data on its Lead Compounds Nolasiban and Linzagolix at the 75th Annual ASRM Meeting in Philadelphia, PA

Geneva, Switzerland and Boston, MA – October 9, 2019- ObsEva SA (NA...

http://www.globenewswire.com/news-release/2019/09/27/1921640/0/en/ObsEva-SA-to-Participate-in-Cantor-Global-Healthcare-Conference-October-2-4-2019.html

ObsEva SA to Participate in Cantor Global Healthcare Conference October 2-4, 2019

Geneva, Switzerland and Boston, MA – September 27, 2019 - ObsEva SA...

http://www.globenewswire.com/news-release/2019/09/11/1914428/0/en/ObsEva-announces-new-composition-of-its-Executive-Committee.html

ObsEva announces new composition of its Executive Committee

Geneva, Switzerland and Boston, MA – September 11, 2019 – ObsEva SA...

All right reserved Buy Stocks Easy , 2019.